Screener
UroGen Pharma URGN Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -51.7%+113pp | -94.8%+55.9pp | -139.8%+0.5pp | -170.6%-41.5pp | -164.4%-30.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.8×+0.4× | 0.6×+0.2× | 0.5×+0.1× | 0.4×0.0× | 0.4×-0.1× | |
| Liquidity | ||||||
| Current ratio | 3.8×-0.3× | 4.7×-1.0× | 4×-2.0× | 4×-5.0× | 4.1×-4.0× | |
| Valuation | ||||||
| Market capitalization | $2.22B+140% | $875.31M+71.7% | $1.1B+144% | $922.97M+76.5% | $635.82M+4.9% | |
| Price / sales | 11.8×+2.0× | 6.2×+0.7× | 10×+5.0× | 9.6×+3.7× | 6.7×-0.4× |
FAQ
- What are UroGen Pharma's profit margins?
- UroGen Pharma (URGN) runs a 89.7% gross margin and a -329.7% operating margin, with a -51.7% net margin.
- Where do UroGen Pharma's ratios come from?
- Every ratio is computed from UroGen Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
